Drugs / MIPASETAMAB UZOPTIRINE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05389462 | Jul 2022 → Apr 2025 | cancer | ADC Therapeutics S.A. | Terminated | No outcome recorded |
| Phase 1 | NCT03700294 | Dec 2018 → Dec 2019 | cancer | ADC Therapeutics S.A. | Terminated | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-07-27 | ADC Therapeutics S.A. | ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid Tumors adctherapeutics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIPASETAMAB UZOPTIRINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095300 ↗ |
| Known as | ADCT-601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05389462 ↗ |
| Route | Intravenous | “Intravenous (IV)” NCT03700294 ↗ |